157 related articles for article (PubMed ID: 11491013)
21. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
22. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model.
Muramaki M; Miyake H; Hara I; Kawabata G; Kamidono S
J Urol; 2004 Oct; 172(4 Pt 1):1485-9. PubMed ID: 15371876
[TBL] [Abstract][Full Text] [Related]
23. Metronomic gemcitabine targeted tumor vascular microenvironment decreases the population of CD133(+) cells in hepatocarcinoma xenografts.
Yi SY; Ruan J; Zhao L; Ke Y; Li XN
Cancer Biomark; 2014; 14(6):427-33. PubMed ID: 25335734
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
[TBL] [Abstract][Full Text] [Related]
26. Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling.
Gong JH; Zheng YB; Zhang MR; Wang YX; Yang SQ; Wang RH; Miao QF; Liu XJ; Zhen YS
Cancer Biol Ther; 2020 Apr; 21(4):332-343. PubMed ID: 31906826
[TBL] [Abstract][Full Text] [Related]
27. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
28. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
[TBL] [Abstract][Full Text] [Related]
29. Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice.
Xiao YS; Tang ZY; Fan J; Zhou J; Wu ZQ; Sun QM; Xue Q; Zhao Y; Liu YK; Ye SL
J Cancer Res Clin Oncol; 2004 Sep; 130(9):546-50. PubMed ID: 15071737
[TBL] [Abstract][Full Text] [Related]
30. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.
Matsumoto K; Nagahara T; Okano J; Murawaki Y
Oncol Rep; 2008 Oct; 20(4):863-72. PubMed ID: 18813828
[TBL] [Abstract][Full Text] [Related]
31. Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer.
Chougule MB; Patel A; Sachdeva P; Jackson T; Singh M
PLoS One; 2011; 6(11):e27394. PubMed ID: 22102891
[TBL] [Abstract][Full Text] [Related]
32. Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model.
Qiu YQ; Zhou J; Kang XS; Ding LM; Yu W; Tan FL; Deng DF
Sci Rep; 2014 Mar; 4():4324. PubMed ID: 24632756
[TBL] [Abstract][Full Text] [Related]
33. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Baker CH; Solorzano CC; Fidler IJ
Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
[TBL] [Abstract][Full Text] [Related]
34. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
35. First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway.
Manu KA; Shanmugam MK; Ramachandran L; Li F; Fong CW; Kumar AP; Tan P; Sethi G
Clin Cancer Res; 2012 Apr; 18(8):2220-9. PubMed ID: 22351692
[TBL] [Abstract][Full Text] [Related]
36. Transforming growth factor-beta and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo.
Liu P; Menon K; Alvarez E; Lu K; Teicher BA
Int J Oncol; 2000 Mar; 16(3):599-610. PubMed ID: 10675495
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo.
Wang W; Hu Z; Huang Y; Zheng H; Sun Q; Yang Q; Zhang Y; Zhang L; Wang W
Biomed Res Int; 2019; 2019():9205851. PubMed ID: 31019975
[TBL] [Abstract][Full Text] [Related]
38. Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model.
Kawaguchi K; Igarashi K; Murakami T; Kiyuna T; Nelson SD; Dry SM; Li Y; Russell TA; Singh AS; Chmielowski B; Unno M; Eilber FC; Hoffman RM
Cell Cycle; 2017 Jun; 16(11):1063-1069. PubMed ID: 28426279
[TBL] [Abstract][Full Text] [Related]
39. MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells.
Ke M; Dong J; Wang Y; Zhang J; Zhang M; Wu Z; Lv Y; Wu R
Int J Biochem Cell Biol; 2018 Aug; 101():39-48. PubMed ID: 29800725
[TBL] [Abstract][Full Text] [Related]
40. Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production of reactive oxygen species in hepatocellular carcinoma.
Wang Z; Gu C; Wang X; Lang Y; Wu Y; Wu X; Zhu X; Wang K; Yang H
Med Oncol; 2019 Oct; 36(12):97. PubMed ID: 31664534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
